Revenue of $505m seems like an impossible dream for 2020. Given...

Revenue of $505m seems like an impossible dream for 2020. Given the current trend the projection is closer to $460m. Nuvaring was meant to save MYX but Amneal looks like they launched on the 12/Dec (https://www.businesswire.com/news/home/20191212005334/en/Amneal-Receives-Abbreviated-New-Drug-Application-Approval) and are already rolling it out. I think being 2nd-3rd to market could also be positive for MYX (as i have said before, but on a diminishing scale), but i have honestly lost all faith in Scott. Take Amneal, they announced approval and roll-out of their Nuvaring generic on the same day. I can't see MYX ever having such a quick turnaround response.

Also, i question my own $460m revenue projection (based on the first 4 months averaged out for the year). MYX lost a contract last month - which we have to speculate about because there is, as always, no noise from the ivory tower and we simply don't know if there are others, why they walked and what kind of an impact that will have on MYX?

Then there is the shorts, they show no signs of abating, and i do not blame them. I now think MYX can go lower than $0.36c, even if it is only on a panicked dumped. I see Feb20 confirming a pretty bleak 1st half with little-to-nothing to get excited about until E4. And i now fear E4 will only restore the lost revenue Mr Richards has overseen and managed.

I think Mr Richards and the board are out of their depth.

Good luck holders, i hope i am wrong, but i have positioned myself according to my new expectations. And they are a re-entry <$36c, Nuvaring approval Feb-June, too late to do anything for revenue 2020, E4 Jun-Dec-Mar/21 and improving fortunes from then.